Log In
BCIQ
Print this Print this
 

ES210

  Manage Alerts
Collapse Summary General Information
Company Aptevo Therapeutics Inc.
DescriptionHumanized, bispecific ADAPTIR molecule targeting CD86and iInterleukin-10 (IL-10)
Molecular Target CD86 (B7-2) ; Interleukin-10 (IL-10)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat ulcerative colitis
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/06/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today